Juvenile idiopathic recurrent parotitis (JIRP) treated with short course steroids, a case series study and one decade follow up for potential autoimmune disorder

Juvenile idiopathic recurrent parotitis (JIRP) in children is a condition characterized with recurrent episodes of idiopathic parotid gland inflammation. Since there are no definitive guidelines for diagnosis and management of this condition, we present a consecutive case series of patients with mor...

Full description

Saved in:
Bibliographic Details
Published in:Pediatric Rheumatology 2024-01, Vol.22 (1), p.8-8, Article 8
Main Authors: Salehzadeh, Farhad, Molatefi, Rasol, Mardi, Ali, Nahanmoghaddam, Negin
Format: Article
Language:English
Subjects:
Analgesics
Antibiotics
Autoimmune diseases
Bacterial infections
Celiac disease
Corticosteroids
Epstein-Barr virus
Exocrine glands
Fever
Health aspects
Hepatitis
Inflammation
Juvenile
Letter to the Editor
Medical research
Mumps
Parotitis
Patients
Pediatrics
Prednisolone
Recurrent parotitis
Vaccines
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Juvenile idiopathic recurrent parotitis (JIRP) in children is a condition characterized with recurrent episodes of idiopathic parotid gland inflammation. Since there are no definitive guidelines for diagnosis and management of this condition, we present a consecutive case series of patients with more than one decade follow up and their dramatic response to short course treatment by prednisolone. We conducted this study by retrospectively reviewed medical charts of children who were diagnosed with JIRP, from 1 January 2002 to 29 February 2023. We performed usual serological tests to exclude some possible background. We administered short course prednisolone on first day of episode as divided dosage (0.5 mg /kg). In this case series of 10 patients (70%) were male, median age of onset was 5 years, duration of episodes 5 days, and the mean course of disease were 3.8 years. The average follows up of patients was near 10 years. In comparison with their natural course of disease all patients showed a dramatic response to treatment on the first day of administration of prednisolone (P Value 0.005). For ten years follow up there was not any additional accompanying autoimmune disorder. Short course prednisolone on first day of each episode and its dramatic and meaningful response in our patients, introduce a new, effective, fast, and inexpensive regimen of therapy in patients with JIRP.
ISSN:1546-0096
1546-0096
DOI:10.1186/s12969-023-00946-0